CLINICAL TRIALS PROFILE FOR SODIUM TETRADECYL SULFATE

All Clinical Trials for sodium tetradecyl sulfate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01347294 ↗	Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations	Unknown status	Oslo University Hospital	Phase 4	2011-08-01	The purpose of this study is to determine the effectiveness of bleomycin, fibrovein and bleomycin and fibrovein in the treatment of venous malformation.
NCT01408732 ↗	Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia	Completed	American Rhinologic Society	Phase 1/Phase 2	2011-02-01	The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.
NCT01408732 ↗	Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia	Completed	University of Minnesota	Phase 1/Phase 2	2011-02-01	The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.
NCT01408732 ↗	Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia	Completed	University of Minnesota - Clinical and Translational Science Institute	Phase 1/Phase 2	2011-02-01	The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.
NCT03311269 ↗	A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency	Recruiting	Vascular Insights, LLC	Phase 2	2017-09-22	VICARES is a prospective randomized, controlled, multi-center, double blind study treating venous insufficiency associated with incompetent saphenous veins with 1% and 3% Sodium Tetradecyl Sulfate (STS) solution utilizing the ClariVein system.
NCT03363633 ↗	Perforator Vein Injection for Symptomatic Venous Disease	Terminated	American College of Phlebology	N/A	2010-03-01	The primary objective of this study is to compare two treatment strategies for symptomatic venous stasis disease with and without venous ulcer. These treatments are compression therapy alone vs. sclerotherapy of refluxing perforating veins with compression.

Clinical Trial Conditions for sodium tetradecyl sulfate

Condition Name

Condition Name for sodium tetradecyl sulfate
Intervention	Trials
Liver Decompensation	1
Pain	1
Venous Disease	1
Cosmesis	1

Condition MeSH

Condition MeSH for sodium tetradecyl sulfate
Intervention	Trials
Epidermal Cyst	1
Telangiectasis	1
Cysts	1
Telangiectasia, Hereditary Hemorrhagic	1

Clinical Trial Locations for sodium tetradecyl sulfate

Trials by Country

Trials by Country for sodium tetradecyl sulfate
Location	Trials
United States	7
Norway	1
Portugal	1
Finland	1
Taiwan	1

Trials by US State

Trials by US State for sodium tetradecyl sulfate
Location	Trials
Washington	1
New Jersey	1
Massachusetts	1
Maryland	1
Connecticut	1

Clinical Trial Progress for sodium tetradecyl sulfate

Clinical Trial Phase

Clinical Trial Phase for sodium tetradecyl sulfate
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	3

Clinical Trial Status

Clinical Trial Status for sodium tetradecyl sulfate
Clinical Trial Phase	Trials
Recruiting	4
Completed	2
Terminated	1

Clinical Trial Sponsors for sodium tetradecyl sulfate

Sponsor Name

Sponsor Name for sodium tetradecyl sulfate
Sponsor	Trials
American College of Phlebology	1
Ellen Dillavou	1
Oulu University Hospital	1

Sponsor Type

Sponsor Type for sodium tetradecyl sulfate
Sponsor	Trials
Other	11
Industry	1